Skip to main content

SYSTEMATIC REVIEW article

Front. Med.
Sec. Infectious Diseases: Pathogenesis and Therapy
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1483864

Efficacy and Safety of Oral Chinese Patent Medicine for Benign Prostatic Hyperplasia: A Network Meta-Analysis of Randomized Controlled Trials

Provisionally accepted
Yiwen Tang Yiwen Tang 1Yuyang Cai Yuyang Cai 1Jiasen Ding Jiasen Ding 2*Ronfu Ji Ronfu Ji 2*Xiong Wang Xiong Wang 2Zejia Zhang Zejia Zhang 2*Feng Xu Feng Xu 2*Zhan Gao Zhan Gao 2*
  • 1 Beijing University of Chinese Medicine, Beijing, China
  • 2 Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China

The final, formatted version of the article will be published soon.

    This paper aims to evaluate the disparities in efficacy and safety across various oral Chinese patent medicines for the treatment of benign prostatic hyperplasia (BPH), using a frequency-based reticulated meta-analysis.The researchers searched the following databases: Web of Science, PubMed, Excerpta Medical Database (Embase), Cochrane Library, China Knowledge Network (CNKI), China Biomedical Literature Service System (SinoMed), Wanfang Data Knowledge Service Platform and China Science and Technology Periodicals Database (VIP). Besides, the researchers collected all randomized controlled trials (RCTs) of oral Chinese patent medicines, as well as simple preparations and simple preparations for benign prostatic hyperplasia from the establishment of the database until July1,2024. After two researchers independently screened literature, extracted data, and evaluated the risk of bias in the included studies, a net meta-analysis was conducted using Stata 16.0 software.Seventy-two RCTs involving 15 oral Chinese patent medicines and a total of 7800 patients were included. Net meta-analysis manifested that J"inkuishenqi capsule (JKSQ) + conventional western medicine (CWM)" was the most effective way in increasing total efficiency ratio. "Huange capsule (HE) + CWM" was the most effective method in decreasing prostate volume. "Qianliesutong capsule (QLST) + CWM" was the most effective approach in decreasing residure volume. "Xialiqi capsule (XLQ) + CWM" was the most effective way in increasing maximum urinary flow rate. "Longbisu capsule (LBS) + CWM" was the most effective method in decreasing international prostate symptom score (IPSS). To reduce the adverse reactions, "HE + CWM" has the best efficacy. Considering both drug efficacy and safety, "Ningmitai capsule (NMT) + CWM" would be the most ideal choice.Conclusion：Based on NMA, JKSQ, HE, QLST, XLQ, LBS, NMT plus CWM have been proved to possess the highest probability of being the best therapy. Due to the limitations of this study, these results should be confirmed through detailed randomized controlled trials.

    Keywords: Network meta-analysis, Benign prostatic hyperplasia, oral Chinese patent medicines, efficacy, Safety

    Received: 09 Sep 2024; Accepted: 19 Nov 2024.

    Copyright: © 2024 Tang, Cai, Ding, Ji, Wang, Zhang, Xu and Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Jiasen Ding, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
    Ronfu Ji, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
    Zejia Zhang, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
    Feng Xu, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
    Zhan Gao, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.